1-2 of 2
Yongyu Wang, MD
Close
Save search
Sort by
Journal Articles

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

Free
John C. Byrd, MD, Ian W. Flinn, MD, Khuda D. Khan, MD, Thomas J. Kipps, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Serge Guzy, PhD, Sanela Bilic, PharmD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD, Susan O’Brien, MD
Journal: Blood
Blood (2006) 108 (11): 2837.
https://doi.org/10.1182/blood.V108.11.2837.2837
Published: 2006
Journal Articles

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

Free
William Bensinger, MD, Sundar Jagannath, MD, Pamela S. Becker, MD, PhD, Kenneth C. Anderson, MD, Edward A. Stadtmauer, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Sanela Bilic, PharmD, Serge Guzy, PhD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD
Journal: Blood
Blood (2006) 108 (11): 3575.
https://doi.org/10.1182/blood.V108.11.3575.3575
Published: 2006